- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis (CF) with the CF transmembrane conductance regulator (CFTR) gene mutation
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 931KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 164KB)
Ivacaftor – November 2023
Ivacaftor: Sachet containing granules 25 mg, Sachet containing granules 50 mg, Sachet containing granules 75 mg, Tablet 150 mg; Kalydeco®
Last updated
1 March 2024